Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD M PUCILLO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1548263106
CMS profile
160158
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,838.47

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,821.57 104
Education $16.90 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD M PUCILLO

NPI 1548263106 · CMS profile ID 160158

Allopathic & Osteopathic Physicians / Family Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548263106?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD M PUCILLO, NPI 1548263106, CMS profile ID 160158. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548263106?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RONALD M PUCILLO, NPI 1548263106, CMS profile ID 160158. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548263106?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RONALD M PUCILLO, NPI 1548263106, CMS profile ID 160158, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1548263106?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $1,838.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–106 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IBSA Pharma Inc. $16.1501/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142983895 CMS
Lilly USA, LLC $22.1901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135375090 CMS
Abbott Laboratories $1.3701/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125118094 CMS
Abbott Laboratories $2.1401/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125118092 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.8501/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086255942 CMS
PFIZER INC. $22.1901/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131115657 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,929.37 135
PY2020 $2,095.84 136
PY2021 $1,848.92 118
PY2022 $1,887.94 118
PY2023 $1,497.34 93
PY2024 $1,838.47 106
PY2025 $1,748.23 98

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $698,468.50 49
PY2024 Principal investigator $1,842,674.31 63
PY2023 Principal investigator $1,086,986.91 926
PY2022 Principal investigator $1,049,470.14 1,455
PY2021 Principal investigator $371,869.55 12
PY2020 Principal investigator $81,954.83 8
PY2019 Principal investigator $5,265.15 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,329.63 12/19/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228736783
Principal investigator 1 PFIZER INC. $3,815.10 11/29/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228728597
Principal investigator 1 PFIZER INC. $3,815.10 11/04/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228737363
Principal investigator 1 PFIZER INC. $2,543.40 10/15/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228729937
Principal investigator 1 ModernaTX, Inc. $118.56 08/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002515
Principal investigator 1 ModernaTX, Inc. $1,547.00 07/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011458
Principal investigator 1 ModernaTX, Inc. $116.55 07/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011460
Principal investigator 1 ModernaTX, Inc. $2,000.00 07/23/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011448
Principal investigator 1 PFIZER INC. $5,230.00 07/11/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228772027
Principal investigator 1 ModernaTX, Inc. $3,024.52 06/18/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002501
Principal investigator 1 ModernaTX, Inc. $51,429.76 06/18/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011442
Principal investigator 1 Novartis Pharmaceuticals Corporation $56,213.23 06/10/2025 Non-covered Recipient Entity
NRG WELLNESS CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190307101
Principal investigator 1 ModernaTX, Inc. $39,015.68 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002521
Principal investigator 1 ModernaTX, Inc. $22,249.76 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011434
Principal investigator 1 ModernaTX, Inc. $22,683.90 05/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011454
Principal investigator 1 ModernaTX, Inc. $682.50 05/07/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011440
Principal investigator 1 ModernaTX, Inc. $25,964.64 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002511
Principal investigator 1 ModernaTX, Inc. $42,119.20 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002519
Principal investigator 1 ModernaTX, Inc. $18,147.12 04/28/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011432
Principal investigator 1 ModernaTX, Inc. $4,641.00 04/02/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011446
Principal investigator 1 ModernaTX, Inc. $3,000.00 04/01/2025 Non-covered Recipient Entity
JAVARA INC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252972773
Principal investigator 1 ModernaTX, Inc. $18,147.12 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002507
Principal investigator 1 ModernaTX, Inc. $23,474.88 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002517
Principal investigator 1 ModernaTX, Inc. $10,197.28 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011452
Principal investigator 1 ModernaTX, Inc. $1,012.08 03/24/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011462
Principal investigator 1 PFIZER INC. $16,400.00 03/01/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228794434
Principal investigator 1 ModernaTX, Inc. $1,012.08 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002503
Principal investigator 1 ModernaTX, Inc. $9,073.56 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002505
Principal investigator 1 ModernaTX, Inc. $33,252.00 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002513
Principal investigator 1 ModernaTX, Inc. $26,359.84 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011444
Principal investigator 1 ModernaTX, Inc. $21,849.75 02/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011456
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,560.00 02/04/2025 Non-covered Recipient Entity
JAVARA, INC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190310701
Principal investigator 1 ModernaTX, Inc. $3,500.00 01/30/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011436
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,075.00 01/30/2025 Non-covered Recipient Entity
JAVARA, INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310669
Principal investigator 1 ModernaTX, Inc. $11,769.12 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252998183
Principal investigator 1 ModernaTX, Inc. $23,244.31 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252998185
Principal investigator 1 ModernaTX, Inc. $9,036.90 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252998187
Principal investigator 1 ModernaTX, Inc. $1,173.15 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252998189
Principal investigator 1 ModernaTX, Inc. $8,133.84 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252998191
Principal investigator 1 ModernaTX, Inc. $6,659.31 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252998193
Principal investigator 1 ModernaTX, Inc. $11,132.88 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002509
Principal investigator 1 ModernaTX, Inc. $21,724.64 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011428
Principal investigator 1 ModernaTX, Inc. $8,106.54 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011430
Principal investigator 1 ModernaTX, Inc. $16,634.86 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011438
Principal investigator 1 ModernaTX, Inc. $16,637.92 01/27/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011450
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,187.64 01/27/2025 Non-covered Recipient Entity
NRG WELLNESS CENTER
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307103
Principal investigator 1 PFIZER INC. $663.65 01/25/2025 Non-covered Recipient Entity
Javara Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1228800967
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,348.00 01/15/2025 Non-covered Recipient Entity
JAVARA, INC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185550938
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,415.50 01/07/2025 Non-covered Recipient Entity
JAVARA, INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310691